A. Mark Schobel
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About A. Mark Schobel
The proxy statement of Aquestive Therapeutics, Inc. reports total compensation of $3,257,284 for A. Mark Schobel in fiscal 2024, including a base salary of $367,500. Disclosed compensation is on record for 4 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Aquestive Therapeutics, Inc. (AQST)
Proxy statement
Start not stated–2025-04-25
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Aquestive Therapeutics, Inc. (AQST) | Chief Innovation and Technology Officer\ | $367,500 | $3,257,284 |
| 2023 | Aquestive Therapeutics, Inc. (AQST) | Chief Innovation and Technology Officer\ | $350,000 | $974,056 |
| 2022 | Aquestive Therapeutics, Inc. (AQST) | Chief Innovation and Technology Officer Keith J. Kendall\ \ Former Chief Executive Officer | $350,000 | $810,019 |
| 2021 | Aquestive Therapeutics, Inc. (AQST) | Chief Innovation and Technology Officer Keith J. Kendall\ \ Former Chief Executive Officer | $350,000 | $939,261 |
Recent activity
No call appearances or filed executive changes recorded yet.